Antiplatelet therapy in secondary stroke prevention

M. K. Crawford, R. L. Talbert

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Stroke is the third leading cause of death in the United States. Antiplatelet agents are the mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy include aspirin (50 - 325 mg) daily, the combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke prevention but is no longer a first-line therapy. This article reviews the literature on antiplatelet agents for secondary stroke prevention.

Original languageEnglish (US)
Pages (from-to)1609-1613
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Issue number10
StatePublished - 2001


  • Antiplatelet
  • Aspirin
  • Clopidogrel
  • Dipyridamole
  • Stroke prevention
  • Thienopyridine ticlopidine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Antiplatelet therapy in secondary stroke prevention'. Together they form a unique fingerprint.

Cite this